JP2019500350A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019500350A5 JP2019500350A5 JP2018529258A JP2018529258A JP2019500350A5 JP 2019500350 A5 JP2019500350 A5 JP 2019500350A5 JP 2018529258 A JP2018529258 A JP 2018529258A JP 2018529258 A JP2018529258 A JP 2018529258A JP 2019500350 A5 JP2019500350 A5 JP 2019500350A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- pharmaceutical composition
- composition according
- item
- tuberin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022053948A JP2022088533A (ja) | 2015-12-14 | 2022-03-29 | 結節性硬化症の処置のためのアンチセンスオリゴマー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562267212P | 2015-12-14 | 2015-12-14 | |
| US62/267,212 | 2015-12-14 | ||
| PCT/US2016/066705 WO2017106375A1 (en) | 2015-12-14 | 2016-12-14 | Antisense oligomers for treatment of tuberous sclerosis complex |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022053948A Division JP2022088533A (ja) | 2015-12-14 | 2022-03-29 | 結節性硬化症の処置のためのアンチセンスオリゴマー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500350A JP2019500350A (ja) | 2019-01-10 |
| JP2019500350A5 true JP2019500350A5 (https=) | 2020-01-30 |
| JP7051683B2 JP7051683B2 (ja) | 2022-04-11 |
Family
ID=59057534
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018529258A Expired - Fee Related JP7051683B2 (ja) | 2015-12-14 | 2016-12-14 | 結節性硬化症の処置のためのアンチセンスオリゴマー |
| JP2022053948A Pending JP2022088533A (ja) | 2015-12-14 | 2022-03-29 | 結節性硬化症の処置のためのアンチセンスオリゴマー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022053948A Pending JP2022088533A (ja) | 2015-12-14 | 2022-03-29 | 結節性硬化症の処置のためのアンチセンスオリゴマー |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP3390635A4 (https=) |
| JP (2) | JP7051683B2 (https=) |
| CA (1) | CA3005131A1 (https=) |
| WO (1) | WO2017106375A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| EP3359685B1 (en) | 2015-10-09 | 2026-01-28 | University Of Southampton | Modulation of gene expression for deregulated protein expression |
| EP3933041B1 (en) | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant retardation |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| IL314915B1 (en) | 2017-01-23 | 2026-02-01 | Regeneron Pharma | Variants of 17-beta-hydroxysteroid dehydrogenase and their uses |
| KR20190139869A (ko) | 2017-04-11 | 2019-12-18 | 리제너론 파마슈티칼스 인코포레이티드 | 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정 |
| SG11202001590RA (en) | 2017-08-25 | 2020-03-30 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| US10961583B2 (en) | 2017-10-11 | 2021-03-30 | Regeneron Phramaceuticals, Inc. | Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation |
| JP7507093B2 (ja) | 2018-03-21 | 2024-06-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | １７β－水酸化ステロイド脱水素酵素１３型（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物およびその使用方法 |
| US12060558B2 (en) | 2018-05-04 | 2024-08-13 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| EP4017979A4 (en) * | 2019-08-19 | 2024-03-27 | Stoke Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATING PROTEIN SPLICING AND EXPRESSION |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| EP4560020A1 (en) * | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
| EP4560019A1 (en) * | 2023-11-22 | 2025-05-28 | Sylentis S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010505897A (ja) * | 2006-10-11 | 2010-02-25 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | インフルエンザターゲット |
| US20120252877A1 (en) * | 2009-08-14 | 2012-10-04 | Theramind Research, Llc | Methods and compositions for treatment of tuberous sclerosis complex |
| EP2475786B1 (en) * | 2009-09-08 | 2016-03-30 | Laboratory Corporation of America Holdings | Compositions and methods for diagnosing autism spectrum disorders |
| PL3041958T4 (pl) * | 2013-09-04 | 2020-11-02 | Cold Spring Harbor Laboratory | Redukcja rozpadu mRNA mediowanego sekwencjami nonsensownymi |
| GB201410693D0 (en) * | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| CN107109411B (zh) * | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| JP7049249B2 (ja) * | 2015-12-14 | 2022-04-06 | コールド スプリング ハーバー ラボラトリー | 中枢神経系疾患の処置のための組成物および方法 |
-
2016
- 2016-12-14 WO PCT/US2016/066705 patent/WO2017106375A1/en not_active Ceased
- 2016-12-14 EP EP16876615.2A patent/EP3390635A4/en not_active Withdrawn
- 2016-12-14 JP JP2018529258A patent/JP7051683B2/ja not_active Expired - Fee Related
- 2016-12-14 CA CA3005131A patent/CA3005131A1/en active Pending
-
2022
- 2022-03-29 JP JP2022053948A patent/JP2022088533A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019500350A5 (https=) | ||
| JP2019501892A5 (https=) | ||
| JP2018538288A5 (https=) | ||
| JP2018538287A5 (https=) | ||
| JP2019500349A5 (https=) | ||
| JP2019500347A5 (https=) | ||
| JP2019500346A5 (https=) | ||
| US6653467B1 (en) | Medicament for treatment of Duchenne muscular dystrophy | |
| US20200155606A1 (en) | Crispr/rna-guided nuclease systems and methods | |
| JP2017519766A5 (https=) | ||
| JP2019500345A5 (https=) | ||
| EP1191098A2 (en) | Pharmaceutical composition for treatment of duchenne muscular dystrophy | |
| EP4240338A1 (en) | <smallcaps/>? ? ?in vivo? ? ? ? ?programmable rna editingvia recruitment of endogenous adars | |
| EP4069830A1 (en) | Engineering circular guide rnas | |
| EP3393523A1 (en) | Endothelium-specific nucleic acid regulatory elements and methods and use thereof | |
| US20200407721A1 (en) | Compounds of chemically modified oligonucleotides and methods of use thereof | |
| TW202321453A (zh) | 反義寡核苷酸及肝糖貯積病第Ia型預防或治療用組成物 | |
| JP2018521669A (ja) | 治療用オリゴヌクレオチド | |
| JP2002325582A (ja) | デュシェンヌ型筋ジストロフィー治療剤 | |
| JP2024079818A (ja) | コレステリルエステル蓄積症の処置のための方法及び組成物 | |
| WO2013134403A1 (en) | Method of treating neurodegenerative diseases with microrna regulators | |
| JP2021523227A5 (https=) | ||
| JP2024524974A (ja) | ナンセンス変異依存ｒｎａ分解機構に基づく病態及び疾患の処置のためのアンチセンスオリゴマー | |
| JPWO2021158858A5 (https=) | ||
| TW202242113A (zh) | 用於治療與多囊蛋白表現相關之病況及疾病之組合物 |